Your shopping cart is currently empty

RIPK2 IN 10W is a potent, selective, and orally active RIPK2 inhibitor with an IC₅₀ of 0.6 nM. RIPK2 IN 10W exhibits high kinase selectivity and suppresses RIPK2 activity, thereby inhibiting NOD-mediated cytokine production induced by muramyl dipeptide (MDP). Targeting RIPK2 has demonstrated potential for the treatment of inflammatory bowel disease.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 7-10 days | 7-10 days | |
| 50 mg | Inquiry | 7-10 days | 7-10 days |
| Description | RIPK2 IN 10W is a potent, selective, and orally active RIPK2 inhibitor with an IC₅₀ of 0.6 nM. RIPK2 IN 10W exhibits high kinase selectivity and suppresses RIPK2 activity, thereby inhibiting NOD-mediated cytokine production induced by muramyl dipeptide (MDP). Targeting RIPK2 has demonstrated potential for the treatment of inflammatory bowel disease. |
| Targets&IC50 | BMDMs:0.3 nM, H9C2 cells:12.33 μM, RIPK2:0.6 nM |
| Synonyms | RIPK2-IN-7 |
| Molecular Weight | 339.41 |
| Formula | C19H22FN5 |
| Cas No. | 2789711-40-4 |
| Smiles | NC1=C2C(=CN(C2=NC=N1)[C@H]3CC[C@@H](N)CC3)C4=C(F)C=C(C)C=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.